Check the spelling or try searching for a more general term.
This whitepaper highlights the role of SLT across the glaucoma disease process, including its utility as a first-line treatment option.
Read a whitepaper addressing the dual role of SLT as both a diagnostic aid and as a highly effective first-line treatment option.
Whether patients with symptomatic floaters should be offered treatment or told to “carry on regardless” continues to be debated. Read the whitepaper to learn more.
Featured in Glaucoma Today, this roundtable discusses the benefits of iTrack™ in targeting multiple sources of outflow resistance.
David Lubeck, MD discusses the role of ABiC in conjunction with SLT and MIGS.